Compare IMMX & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMX | SPTX |
|---|---|---|
| Founded | 2014 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.8M | 929.8M |
| IPO Year | 2021 | 2026 |
| Metric | IMMX | SPTX |
|---|---|---|
| Price | $7.92 | $20.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $24.05 | ★ $37.13 |
| AVG Volume (30 Days) | ★ 1.2M | 235.0K |
| Earning Date | 11-12-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.78 | $15.79 |
| 52 Week High | $15.10 | $28.38 |
| Indicator | IMMX | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 48.16 |
| Support Level | $7.82 | $18.79 |
| Resistance Level | $9.04 | $22.53 |
| Average True Range (ATR) | 0.62 | 1.46 |
| MACD | 0.16 | 0.03 |
| Stochastic Oscillator | 41.81 | 29.08 |
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.